Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer
when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and
PLD/carboplatin.
Phase:
Phase 3
Details
Lead Sponsor:
AGO Research GmbH
Collaborators:
ANZGOG Arbeitsgemeinschaft Gynaekologische Onkologie Austria ARCAGY/ GINECO GROUP Australia New Zealand Gynaecological Oncology Group Scottish Gynaecological Cancer Study Group